Trial Profile
A retrospective study evaluating medication adherence to glucagon-like peptide-1 receptor agonists (exenatide and liraglutide) in medicare population with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Jan 2017 New trial record
- 11 Jan 2017 Results published in the Advances in Therapy